| 1 |
35110416 | Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. | 2022 May 2 |
2 |
| 2 |
35114682 | Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching. | 2022 |
1 |
| 3 |
35409939 | Predicting Response to Anthracyclines in Ovarian Cancer. | 2022 Apr 2 |
1 |
| 4 |
33069665 | A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. | 2021 Jul |
2 |
| 5 |
33376533 | Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer. | 2021 Feb |
3 |
| 6 |
33517316 | Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study. | 2021 Feb |
1 |
| 7 |
33542544 | Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients. | 2021 Mar |
1 |
| 8 |
33613693 | Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. | 2021 |
1 |
| 9 |
33664949 | The relationship between NFKB, HER2, ER expression and anthracycline -based neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia. | 2021 Mar |
1 |
| 10 |
33806441 | Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008-2012. | 2021 Mar 4 |
2 |
| 11 |
34014249 | Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. | 2021 Jul 1 |
3 |
| 12 |
34014297 | Anthracycline Use in ERBB2-Positive Breast Cancer: It Is Time to Re-TRAIN. | 2021 Jul 1 |
1 |
| 13 |
34037346 | Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. | 2021 May 26 |
1 |
| 14 |
34076352 | A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy. | 2021 Jul |
4 |
| 15 |
34268990 | Sequential anthracycline and weekly paclitaxel might be more effective compared to docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients. | 2021 May-Jun |
1 |
| 16 |
34327363 | Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. | 2021 Jun |
4 |
| 17 |
34367947 | Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. | 2021 |
1 |
| 18 |
34406849 | Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? | 2021 Nov 10 |
1 |
| 19 |
34564997 | Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data. | 2021 Jul-Aug |
2 |
| 20 |
34699004 | Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. | 2021 Dec |
1 |
| 21 |
31251346 | Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. | 2020 Jan 1 |
1 |
| 22 |
32331711 | Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction. | 2020 Jun 15 |
1 |
| 23 |
32476183 | Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial. | 2020 Sep |
1 |
| 24 |
32780321 | Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer. | 2020 Nov |
2 |
| 25 |
32862625 | Is there a role of anthracycline use in the management of de novo HER-2 positive metastatic breast cancer? | 2020 May-Jun |
1 |
| 26 |
33065805 | Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab. | 2020 Sep |
1 |
| 27 |
33255658 | Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. | 2020 Nov 25 |
1 |
| 28 |
33299647 | Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines. | 2020 Nov 15 |
1 |
| 29 |
33328545 | Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer. | 2020 Dec 16 |
1 |
| 30 |
33335565 | Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. | 2020 |
1 |
| 31 |
33425535 | Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients. | 2020 Dec 7 |
1 |
| 32 |
30418380 | Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. | 2019 Jan |
1 |
| 33 |
30465156 | Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. | 2019 Feb |
2 |
| 34 |
30665463 | A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. | 2019 Jan 21 |
3 |
| 35 |
30734437 | Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. | 2019 Mar |
1 |
| 36 |
30810890 | Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients. | 2019 Jul |
5 |
| 37 |
30826225 | Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. | 2019 Apr |
1 |
| 38 |
31082851 | Cardiotoxicity of HER2-targeted therapies. | 2019 Jul |
2 |
| 39 |
31165940 | HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. | 2019 Sep |
2 |
| 40 |
31424664 | The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study. | 2019 May-Jun |
1 |
| 41 |
31430226 | Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. | 2019 Oct 10 |
1 |
| 42 |
31517852 | Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report. | 2019 Sep |
1 |
| 43 |
31534839 | Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy. | 2019 |
3 |
| 44 |
29223479 | Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. | 2018 Jan |
2 |
| 45 |
29253081 | Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. | 2018 Mar 1 |
1 |
| 46 |
29330719 | Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. | 2018 Apr |
2 |
| 47 |
29464058 | Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity. | 2018 Jan 19 |
1 |
| 48 |
29678165 | Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. | 2018 Apr 20 |
3 |
| 49 |
29745076 | Ten years of using adjuvant trastuzumab in breast cancer in Serbia - Single institution experience. | 2018 Mar-Apr |
1 |
| 50 |
29752560 | Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review. | 2018 May 11 |
2 |